Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma.
Sang Hun Lee, Do Young Kim, Ho-Jin Shin
✦ AI-curated · Sources linked
In 30 seconds
This phase I, 3 + 3 dose-escalation study assessed adding melphalan to bendamustine, etoposide, and busulfan conditioning for autologous stem-cell transplantation in 12 patients with high-risk or relapsed/refractory non-Hodgkin lymphoma; 10 were in complete response before transplantation. All patients developed grade ≥ 3 hematologic toxicity. At 70 mg/m² melphalan, two dose-limiting toxicities occurred, including one sepsis-related death. The 3-month complete response rate was 90.9%; at median follow-up of 57.5 months, progression-free and overall survival rates were 58.3 and 66.7%, respectively.
Key findings
- All 12 patients experienced grade ≥ 3 hematologic toxicities.
- At 70 mg/m² melphalan, two dose-limiting toxicities occurred: grade 4 mucositis and one sepsis-related death.
- The 3-month complete response rate was 90.9%.
- At median follow-up of 57.5 months, progression-free survival and overall survival rates were 58.3 and 66.7%, respectively.
Why it matters
The study provides early safety and outcome data for an intensified conditioning regimen in a high-risk or relapsed/refractory lymphoma population undergoing autologous transplantation. The severe toxicities observed, particularly at the 70 mg/m² dose, are important to weigh alongside the reported response and survival outcomes. These preliminary results help frame the need for further evaluation rather than establish comparative benefit.
What to keep in mind
The phase I design and small sample limit interpretation; the highest-dose cohort was prematurely terminated.